Research updates: retatrutide news by email
Last reviewed by retainfo editorial team. How we review content.
If you follow retatrutide for work, whether as a researcher, clinician, pharmacist, journalist or policy-maker, we can tell you when something changes. A short email, only when there is something worth knowing.
What you will get
- Trial readouts. When a TRIUMPH, TRANSCEND or other registered trial reports, with both estimands and the placebo figures, and a link to the updated trial page.
- Regulatory milestones. Filings, decisions and safety communications from the MHRA, FDA, EMA and NICE.
- UK harm-reduction alerts. MHRA enforcement and health alerts about products sold as retatrutide, as covered in the safety section.
- Corrections. When we change a figure on the site, what changed and why, in line with our editorial policy.
Expect a handful of emails a year, not a weekly newsletter. Recent examples of the kind of thing we would send are in the news section.
What you will not get
No marketing, no sponsored content, and nothing from anyone else. We do not sell, share or rent the list, and every email has an unsubscribe link. This site never links to, names or recommends anyone who sells peptides.
Your details
We store your name and email on our own server, only to send these updates, and only because you ticked the box. The privacy notice has the detail, including how to have your details deleted.